FTC Settlement With USAP Puts Billions in PE Healthcare Deals on Notice

The Federal Trade Commission’s settlement with U.S. Anesthesia Partners signals a new era of regulatory risk for the private equity industry's lucrative healthcare consolidation playbook.

The U.S. Federal Trade Commission has finalized a settlement with private equity-backed U.S. Anesthesia Partners, resolving a landmark case that accused the provider of creating a monopoly in Texas that cost consumers tens of millions of dollars annually. The agreement, announced in late April, marks a significant step in the government's campaign to curb anticompetitive consolidation in the healthcare sector.

"In considering the best interests of our patients, clinicians, and hospital partnerships, we felt it was important to resolve this now so that USAP can remain laser focused on providing high-quality anesthesia services to our communities," Dr. Scott Holliday, chairman of USAP’s board, said in a statement, while maintaining the company "operated responsibly" and denying any wrongdoing.

The settlement, the terms of which remain confidential pending negotiation, follows a 2023 lawsuit where the FTC alleged USAP, a portfolio company of Welsh, Carson, Anderson & Stowe, systematically acquired nearly every large anesthesia practice in Texas. The FTC claimed this "roll-up" strategy allowed USAP to demand significantly higher prices. The agency had previously settled with Welsh Carson in early 2025 after a federal judge had initially tossed the case against the private equity firm itself, arguing it was not directly responsible for its portfolio company's actions.

This settlement puts the private equity industry's estimated $2 trillion in healthcare assets on notice, suggesting that the "roll-up" acquisition strategy faces a heightened risk of antitrust challenges. The outcome could reshape contracting dynamics for hospitals and ambulatory surgery centers (ASCs), potentially fostering more competition among service providers and impacting future deal valuations across the health services landscape.

A Test Case for PE "Roll-Ups"

The case against USAP and its backers, which also include Berkshire Partners and Singapore's sovereign wealth fund GIC Capital, was a novel test of the FTC's ability to combat serial acquisitions. The "roll-up" playbook, a favored strategy in private equity, involves acquiring many small companies in the same sector and consolidating them into a single, dominant entity. While individual acquisitions may be too small to trigger regulatory review, the cumulative effect can stifle competition.

The FTC's original 2023 complaint alleged that after cornering the market, USAP and Welsh Carson drove up prices through billing agreements and sidelined a competitor by agreeing to keep it out of USAP's territory. USAP said it agreed to the settlement to avoid the "enormous time, energy, and financial commitments" of prolonged litigation.

The resolution comes as antitrust regulators, armed with refreshed merger guidelines from the Biden administration, intensify their focus on healthcare. In March, the FTC established a new, cross-departmental task force to proactively investigate and challenge potentially anticompetitive conduct in healthcare markets, coordinating efforts with the Department of Justice and HHS.

Broader Implications for Healthcare

For healthcare providers, particularly ASCs, the FTC's increased scrutiny could be a welcome development. Industry analysts suggest that limiting aggressive consolidation by large, PE-backed groups could foster a more competitive environment for anesthesia services, potentially leading to more favorable contracting terms for surgery centers.

The settlement also highlights a growing body of research linking private equity ownership to negative outcomes in healthcare. Studies have shown that PE ownership often leads to higher prices for consumers, lower customer satisfaction, and in some cases, poorer medical outcomes. The recent bankruptcies of PE-backed hospital systems like Steward Health Care and Prospect Medical Holdings have drawn further public and political attention to the issue.

While the confidential terms of the USAP settlement mean the direct financial and operational consequences are not yet public, the signal to the market is clear. The FTC, even with its current two-commissioner board, is committed to using its authority to challenge consolidation in healthcare, forcing private equity firms to reconsider the risks of a strategy that has been a reliable source of profits for more than a decade.

This article is for informational purposes only and does not constitute investment advice.